HOWL Stock Forecast: Werewolf Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.94
−4.66% on the day

The median 12-month analyst price target for Werewolf Therapeutics, Inc. is $7. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 90 of 100 as at 21 Nov 2026 — among the strongest tenth.

Market cap
$47.9M
Ticker Nerd rank
90/ 100
Median analyst target
$7.00
Analysts covering
1
Revenue$21.0M
Operating income$7.2M
Net income$3.7M
Free cash flow$6.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.1%
1M
−10.5%
YTD
+48.3%
1Y
+10.0%
From 52W high
−14.5%
From 52W low
+205.2%
$0.31
$1.10
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Werewolf Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
90/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
85
Accruals
81
Issuance
80
Value
78
Volatility
62
Momentum
56
Quality
53
Revisions
48

Growth (85): Sales and profits are climbing, and climbing faster than before.

Revisions (48): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

HOWL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on HOWL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Jan 26Apr 26Jul 26Oct 26HOWLHigh $10.00Median $7.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1
Buy
0
Hold
0
Sell
$4.00
Low
$7.00
Median
$10.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
19 Dec 2025HC Wainwright & Co.MaintainsBuy$10 → $4.00
18 Nov 2025B of A SecuritiesMaintainsBuy—
25 Aug 2025B of A SecuritiesMaintainsBuy—
21 Aug 2025JMP SecuritiesMaintainsMarket Outperform—
9 May 2025WedbushMaintainsOutperform—
12 Mar 2025HC Wainwright & Co.ReiteratesBuy—
12 Mar 2025WedbushReiteratesOutperform—
14 Jan 2025JMP SecuritiesMaintainsMarket Outperform—
19 Nov 2024HC Wainwright & Co.ReiteratesBuy—
2 July 2024HC Wainwright & Co.ReiteratesBuy—
26 June 2024HC Wainwright & Co.ReiteratesBuy—
26 June 2024JMP SecuritiesReiteratesMarket Outperform—
4 June 2024JMP SecuritiesReiteratesMarket Outperform—
3 June 2024HC Wainwright & Co.ReiteratesBuy—
24 May 2024HC Wainwright & Co.ReiteratesBuy—
6 May 2024HC Wainwright & Co.ReiteratesBuy—
6 May 2024JMP SecuritiesReiteratesMarket Outperform—
3 Apr 2024JMP SecuritiesInitiatesMarket Outperform—
7 Mar 2024HC Wainwright & Co.MaintainsBuy—
15 Nov 2023HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for HOWL.

Market Radar

This page is one stock. Monday covers all of them.

HOWL appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

HOWL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Werewolf Therapeutics, Inc. returned +10.0% against +6.9% for the S&P 500, dividends included.

HOWL vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140Jan 26Apr 26Jul 26Oct 26HOWLS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

HOWL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
2.2×

Cheaper than 46% of US stocks

Price / book
6.8×

Cheaper than 12% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−154.6%

Higher than 9% of US stocks

Return on assets
−26.1%

Higher than 16% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Werewolf Therapeutics, Inc. has a market value of $47.9M and an enterprise value of $6.0M.

  • Revenue in the twelve months to 30 June 2026: $21.0M.

  • Net income over the same four quarters: −$34.6M, a −164.8% net margin.

  • Diluted earnings per share, trailing twelve months: −$0.76.

  • Free cash flow in the twelve months to 30 June 2026: −$30.1M.

  • Shares outstanding: 48.6M.

  • Werewolf Therapeutics, Inc. employs 39 people — $538K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

HOWL and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
HOWLWerewolf Therapeutics, Inc.$47.9M90
MISTMilestone Pharmaceuticals, Inc.$46.2M29
TNXPTonix Pharmaceuticals Holding Corp.$46.2M22
RNXTRenovoRx, Inc.$45.5M34
APLMApollomics, Inc.$45.3M9
VRCAVerrica Pharmaceuticals, Inc.$47.1M49
GANXGain Therapeutics, Inc.$44.5M32

Take a look at HOWL’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Werewolf Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about HOWL

What is the HOWL stock price forecast for 2026-2027?

The median 12-month analyst price target for Werewolf Therapeutics, Inc. is $7, with estimates ranging from $4 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is HOWL stock a buy right now?

Of the 1 analyst covering Werewolf Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Werewolf Therapeutics, Inc. 90 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank HOWL?

As at 21 Nov 2026, Werewolf Therapeutics, Inc. ranks 90 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (85 of 100).

Will HOWL stock go up?

No one can know that. What the data says: the median 12-month target from 1 analyst is $7, and Ticker Nerd's factor model ranks Werewolf Therapeutics, Inc. 90 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the HOWL stock forecast for 2030?

No analyst covering Werewolf Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HOWL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $10 over the next 12 months.

How has HOWL stock performed over the past year?

Werewolf Therapeutics, Inc. returned +10.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Werewolf Therapeutics, Inc. do?

Werewolf Therapeutics Inc. is a biopharmaceutical company focused on developing conditionally activated therapeutics designed to stimulate the immune system for the treatment of cancer and other immune-mediated conditions. The company’s current work centers on its proprietary PREDATOR platform, which is used to create INDUKINE and INDUCER molecules intended to activate selectively in diseased tissue while limiting activity in healthy tissue.

Company

About Werewolf Therapeutics, Inc.

Werewolf Therapeutics Inc. is a biopharmaceutical company focused on developing conditionally activated therapeutics designed to stimulate the immune system for the treatment of cancer and other immune-mediated conditions. The company’s current work centers on its proprietary PREDATOR platform, which is used to create INDUKINE and INDUCER molecules intended to activate selectively in diseased tissue while limiting activity in healthy tissue. Its pipeline includes immune-modulating candidates aimed at solid tumors and specific cancer targets, reflecting a concentration on oncology and immunotherapy. Werewolf Therapeutics Inc. operates as a clinical-stage developer of advanced biologic therapies, with research and development activities spanning tumor-directed immune activation and targeted protein engineering. Headquartered in Watertown, Massachusetts, the company is positioned within the biotechnology sector as a specialist in next-generation cancer therapeutics.

CEO Dr. Daniel J. Hicklin Ph.D. · 39 employees · United States · https://werewolftx.com